Rosa to Present Psoriasis Collaboration Results at 2013 AAPS National Biotechnology Conference

SAN CARLOS, Calif. - May 26, 2013 - PRLog -- Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that results from its Psoriasis PhysioPD collaboration will be presented at the 2013 AAPS National Biotechnology Conference in San Diego, CA, May 20-22. Dr. Rebecca Baillie will present a poster entitled “Physiological model to investigate and prioritize targets for psoriasis”. The presentation will describe the development and use of a custom-designed Psoriasis PhysioMap®, which provided information and methodology that enabled key decisions in early development target prioritization. The map was built based on literature data, and it was critically reviewed by R&D scientists and disease experts. The presentation will show how the Map was used to evaluate the roles of drug targets in disease pathways, their potential interactions, and their relative contributions to efficacy potential. This process has informed the selection and prioritization of drug development targets, and it has set the stage for the development of a quantitative PhysioPD model that will further elucidate and prioritize target potential.

“We are pleased to present some of the results of the research we have been conducting in skin diseases. This work has long-term implications in the development of therapeutics for chronic inflammatory conditions in the skin and other tissues.” said Dr. Christina Friedrich, Principal and Chief Engineer, PhysioPD, at Rosa.

About Rosa

Rosa informs our customer’s most critical decisions – from preclinical through clinical development – with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/ pharmacodynamic (PK/PD) models and Rosa’s innovative PhysioPD™ models. With these approaches, Rosa’s clients collaborate in model creation and testing, retain the final model, and acquire the ability to use it and understand its implications for their drug development programs. Rosa’s staff have unparalleled professional experience in using drug-disease modeling and simulation (M&S) to accelerate drug development and have completed hundreds of engagements with dozens of clients in multiple therapeutic areas. The Rosa team is unique in their breadth and depth of disease area experience, which includes metabolic and cardiovascular diseases, oncology, gastro-intestinal disease, inflammatory diseases, immune dysfunction (including rheumatoid arthritis), pain, skin conditions, respiratory disorders, and antibacterials/antivirals.
More information can be found online at http://www.rosaandco.com

Rosa and the Rosa logo are registered trademarks of Rosa & Co. LLC.

For more information:

Visit our website: http://www.rosaandco.com (http://www.rosaandco.com/webinar.html)